Blocking SETDB1 in a mouse cancer model significantly increased the cell-killing activity of immune cells against cancer cells, and the tumors shrank significantly after treatment with an immune checkpoint inhibitor (PD-1 blockade), suggesting the potential of SETDB1 as a promising target for immunotherapy. The gene discussed is SETDB1; the disease is cancer.